New data suggest Oruka’s IL-23 mAb could be competitive in psoriasis 

Oral psoriasis therapies may be closing the efficacy gap with injectables, but interim Phase IIa data from Oruka’s half-life-extended anti-IL-23 injectable could position it among the most effective plaque psoriasis therapies to date. 

In interim data announced Monday, Oruka Therapeutics Inc. (NASDAQ:ORKA) said its anti-IL-23 mAb ORKA-001 met the primary endpoint of Psoriasis Area and Severity Index (PASI) 100 at week 16 in the 84-patient Phase IIa EVERLAST-A trial. The result sent Oruka’s shares up 11% to $76.39 Monday, for a market cap of about $3.8 billion...